""to align resources""
""the insights gained are invaluable for understanding progranulin-related neurodegeneration,""
""Analyses are ongoing, and it is premature to draw conclusions about the specific factors contributing to the""
Alector is cutting approximately 49% of its workforce after its lead drug candidate, latozinemab, failed to meet its Phase 3 goal of slowing dementia progression. The company is terminating a planned continuation study and has removed the drug from its public pipeline. A WARN filing lists 75 layoffs: 49 at the South San Francisco headquarters and 26 remote employees across 13 states, effective between Dec. 22 and April 15. Scientist and clinical roles are heavily affected, including five vice presidents and a senior VP. The head of R&D is resigning. Company statements emphasize ongoing analyses and intent to share results with the scientific community.
Read at SFGATE
Unable to calculate read time
Collection
[
|
...
]